Lactobacillus fermentum Ess-1 with unique growth inhibition of vulvo-vaginal candidiasis pathogens

Rönnqvist, Daniel; Forsgren-Brusk, Ulla; Husmark, Ulrika; Grahn-Håkansson, Eva

doi:10.1099/jmm.0.47226-0

Cited by 34 publications

(29 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent study, the growth and virulence of Escherichia coli and Gardnerella vaginalis were inhibited by the L. fermentum strain SK5 (Kaewnopparat et al, 2013). Similar effects were observed for the L. fermentum strain Ess-1, which was shown to inhibit C. albicans and C. glabrata growth (Rönnqvist et al, 2007) and for L. fermentum HV6b MTCC 10770, which was able to reduce the growth of Bacteroides , G. vaginalis , Mobiluncus , Staphylococcus spp., and Streptococcus spp L. fermentum antimicrobial actions have been attributed to its ability to produce a bacteriocin-like compound (Sabia et al, 2014) and to secrete the antimicrobial peptide fermenticin HV6b (Kaur et al, 2013). Additionally, Pascual et al (2010) demonstrated that L. fermentum L23 presents in vivo probiotic actions against vaginitis by treating and preventing E. coli -induced infections.…”

Section: Discussionsupporting

confidence: 65%

Lactobacillus fermentum ATCC 23271 Displays In vitro Inhibitory Activities against Candida spp.

et al. 2016

View full text Add to dashboard Cite

Lactobacilli are involved in the microbial homeostasis in the female genital tract. Due to the high prevalence of many bacterial diseases of the female genital tract and the resistance of microorganisms to various antimicrobial agents, alternative means to control these infections are necessary. Thus, this study aimed to evaluate the probiotic properties of well-characterized Lactobacillus species, including L. acidophilus (ATCC 4356), L. brevis (ATCC 367), L. delbrueckii ssp. delbrueckii (ATCC 9645), L. fermentum (ATCC 23271), L. paracasei (ATCC 335), L. plantarum (ATCC 8014), and L. rhamnosus (ATCC 9595), against Candida albicans (ATCC 18804), Neisseria gonorrhoeae (ATCC 9826), and Streptococcus agalactiae (ATCC 13813). The probiotic potential was investigated by using the following criteria: (i) adhesion to host epithelial cells and mucus, (ii) biofilm formation, (iii) co-aggregation with bacterial pathogens, (iv) inhibition of pathogen adhesion to mucus and HeLa cells, and (v) antimicrobial activity. Tested lactobacilli adhered to mucin, co-aggregated with all genital microorganisms, and displayed antimicrobial activity. With the exception of L. acidophilus and L. paracasei, they adhered to HeLa cells. However, only L. fermentum produced a moderate biofilm and a higher level of co-aggregation and mucin binding. The displacement assay demonstrated that all Lactobacillus strains inhibit C. albicans binding to mucin (p < 0.001), likely due to the production of substances with antimicrobial activity. Clinical isolates belonging to the most common Candida species associated to vaginal candidiasis were inhibited by L. fermentum. Collectively, our data suggest that L. fermentum ATCC 23271 is a potential probiotic candidate, particularly to complement candidiasis treatment, since presented with the best probiotic profile in comparison with the other tested lactobacilli strains.

show abstract

Section: Discussionsupporting

confidence: 65%

Lactobacillus fermentum ATCC 23271 Displays In vitro Inhibitory Activities against Candida spp.

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The method has earlier been used to demonstrate the in vitro growth inhibition of different isolates of lactobacilli on pathogenic bacteria in the female urogenital region [23] and to study the inhibitory effect of alpha-hemolytic streptococci on the otitis media pathogens Streptococcus pneumoniae , Haemophilus influenzae and Moraxella catarrhalis [24]. Kõll et al [25] used the deferred antagonism method to test the inhibitory capacity against mutans streptococci and C. albicans .…”

Section: Discussionmentioning

confidence: 99%

Growth inhibition of oral mutans streptococci and candida by commercial probiotic lactobacilli - an in vitro study

et al. 2010

View full text Add to dashboard Cite

BackgroundProbiotic bacteria are suggested to play a role in the maintenance of oral health. Such health promoting bacteria are added to different commercial probiotic products. The aim of the study was to investigate the ability of a selection of lactobacilli strains, used in commercially available probiotic products, to inhibit growth of oral mutans streptococci and C. albicans in vitro.MethodsEight probiotic lactobacilli strains were tested for growth inhibition on three reference strains and two clinical isolates of mutans streptococci as well as two reference strains and three clinical isolates of Candida albicans with an agar overlay method.ResultsAt concentrations ranging from 109 to 105 CFU/ml, all lactobacilli strains inhibited the growth of the mutans streptococci completely with the exception of L. acidophilus La5 that executed only a slight inhibition of some strains at concentrations corresponding to 107 and 105 CFU/ml. At the lowest cell concentration (103 CFU/ml), only L. plantarum 299v and L. plantarum 931 displayed a total growth inhibition while a slight inhibition was seen for all five mutans streptococci strains by L. rhamnosus LB21, L. paracasei F19, L. reuteri PTA 5289 and L. reuteri ATCC 55730. All the tested lactobacilli strains reduced candida growth but the effect was generally weaker than for mutans streptococci. The two L. plantarum strains and L. reuteri ATCC 55730 displayed the strongest inhibition on Candida albicans. No significant differences were observed between the reference strains and the clinical isolates.ConclusionThe selected probiotic strains showed a significant but somewhat varying ability to inhibit growth of oral mutans streptococci and Candida albicans in vitro.

show abstract

“…Candida alters the normal vaginal flora. During probiotic treatment, probiotic metabolites reach the entire body, including the vagina, through the bloodstream and cause changes in the normal vaginal flora [15]. …”

Section: Discussionmentioning

confidence: 99%

“…They play a fundamental role in suppression of potential pathogens. Lactobacilli administered within the genital tract act as prophylaxis, improving and strengthening the genital microflora and defending against bacterial infections [15]. Two major groups of these microorganisms include probiotic lactobacillus and Bifidobacterium [16, 17].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison between Fluconazole with Oral Protexin Combination and Fluconazole in the Treatment of Vulvovaginal Candidiasis

Nouraei

Akbari

Jorjani

et al. 2012

ISRN Obstetrics and Gynecology

View full text Add to dashboard Cite

Background. According to the limited studies reporting new treatments for vulvovaginal candidiasis, this study was designed to compare the combination of fluconazole and oral protexin with fluconazole in the treatment of vulvovaginal candidiasis. Methods. A double-blind clinical trial was conducted, involving 90 women who were referred to the gynecology clinic. Vulvovaginal candidiasis was diagnosed with itching, cheesy vaginal discharge, and any one of the following: dysuria, pH < 4.5, dyspareunia, vulvar erythema, or vulvar edema and if branched hyphae and Candida buds were visible after addition of KOH 10% in the culture and the result of cultivation in Sabouraud's dextrose agar medium was positive. Patients were randomly classified into two groups Absence of discharge, itching, and negative culture results 5–7 days after completion of treatment indicated treatment success. Data in this study were analyzed using the SPSS version 17.0 software. Results. The combinations, fluconazole-oral protexin and fluconazole-placebo, were equally effective in reduction of complaints and symptoms, but fluconazole-oral protexin combination elicited a better therapeutic response (χ 2 = 0.01, P = 6.7). In addition, fluconazole-oral protexin combination treatment demonstrated better recovery time (t = −2.04, P = 0.04). Conclusion. This study demonstrated that complementary treatment with probiotic Lactobacillus increased the efficacy of fluconazole in treatment of vulvovaginal candidiasis. Further research is recommended.

show abstract

Lactobacillus fermentum Ess-1 with unique growth inhibition of vulvo-vaginal candidiasis pathogens

Cited by 34 publications

References 18 publications

Lactobacillus fermentum ATCC 23271 Displays In vitro Inhibitory Activities against Candida spp.

Lactobacillus fermentum ATCC 23271 Displays In vitro Inhibitory Activities against Candida spp.

Growth inhibition of oral mutans streptococci and candida by commercial probiotic lactobacilli - an in vitro study

Comparison between Fluconazole with Oral Protexin Combination and Fluconazole in the Treatment of Vulvovaginal Candidiasis

Contact Info

Product

Resources

About